BeOne's $50 bln biotech rise draws US-China policy scrutiny

BeOne, a $50 billion biotech firm, reported strong earnings driven by its cancer drugs, as Washington and Beijing increasingly treat advanced therapies like AI and chips in geopolitics.

Read the full story at Reuters AI ↗

Timeline · 1 report

2026-11-09 08:15 · Reuters AI
Breakingviews - COMMENTARY: Biotech rising star has lifeline from geopolitics

More stories

Nvidia probes CEO Jensen Huang over affair with suspected Chinese spy — Axios AI+
Anthropic agrees $3.4bn deal for gas-fired generators to power AI data centres — Financial Times AI
DeepSeek's Harness agent app reaches 1.54 million daily users — Bloomberg AI
Asian markets bounce back after a recovery for AI stocks on Wall Street — The Globe and Mail
NVIDIA, Rebellions and SK Telecom Expand Korea's Sovereign AI Push — NVIDIA Newsroom
STATERA Library adds Korean chapters 18-25 covering SLAM topics from localization to future trends — DEV Community — AI
Hydra-PSIE expands 'Coeziune OM–IA' DOI registry to 41 published works — DEV Community — AI
Rubio to discuss Iran, Ukraine and AI with G7 allies in France — AP News

Get the daily brief of stories like this at 6:30 every morning →